A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma

  • Briggs, Peter (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/49746/MonH-2019-170516(v3)
NMA Project ID Code: 49746
Monash Health Ref: RES-19-0000015A
Effective start/end date4/09/193/09/24


  • clinical trial
  • phase 3 study
  • treatment efficacy
  • Mesothelioma